share_log

Bull Horn Holdings Corp. Combination Partner Coeptis Therapeutics Enters Into Exclusive Option Agreement With University Of Pittsburgh For Rights To CAR-T Technologies Designed To Target Multiple Cancer Indications, Including Hematologic And Solid Tumors

Benzinga Real-time News ·  May 17, 2022 07:21

Option agreement comprises three technologies and associated patent portfolios

Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms

WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial cancer indications under development...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment